Skip to main content
. 2015 Apr 1;35(13):5271–5283. doi: 10.1523/JNEUROSCI.0650-14.2015

Figure 4.

Figure 4.

LRRK2 KO prevents neurotoxicity and diminishes microglial activation after in vivo cortical Tat injection. A–G, IHC for MAP2 (red), Iba1 (green), and DAPI (blue) in saline control animals (A, 10×; D, 10×), Tat-treated WT mice (B, 10×; C, 60×), and Tat-treated KO mice (E, 10×; F, 60×). G, LRRK2 KO significantly increases MAP2 expression in Tat-treated animals. H–N, IHC for CD11b (red), TUJ1 (green), and DAPI (blue) in saline control animals (H, 10×; K, 10×), Tat-treated WT mice (I, 10×; J, 60×), and Tat-treated KO mice (L, 10×; M, 60×). N, LRRK2 KO significantly increases TUJ1 expression in Tat-treated animals (*p < 0.05, **p < 0.01, one-way ANOVA with Newman–Keuls post hoc test). Scale bars: A, B, D, E, H, I, K, L, 60 μm; C, F, J, M, 11 μm.